Evidence map›Paper›PMID 38183837›Full record

ArticleVeterinary immunology and immunopathology2024

Development of a next-generation sequencing protocol for the canine T cell receptor beta chain repertoire.

Cindy L Zuleger, Rene Welch Schwartz, Irene M Ong, Michael A Newton, David M Vail, Mark R Albertini

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary immunology and immunopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Translational History and Hope of Immunotherapy of Canine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Cindy L ZulegerCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
Rene Welch SchwartzDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
Irene M OngCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States; Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States; Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
Michael A NewtonCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States; Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
David M VailCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States.
Mark R AlbertiniCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States; Department of Dermatology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States; The Medical Service, William S. Middleton Memorial Veterans Hospital, Madison, WI, United States. Electronic address: mralbert@wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · USWilliam S. Middleton Memorial Veterans Hospital · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanomaI01BX003916 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI MARK R ALBERTINI · 2019 to 2026
–
BLRD VA I01 BX003916NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

Profiling the T cell receptor (TCR) repertoire using next-generation sequencing has become common in both human and translational research. Companion dogs with spontaneous tumors, including canine melanoma, share several features, e.g., natural occurrence, shared environmental exposures, natural outbred population, and immunocompetence. T cells play an important role in the adaptive immune system by recognizing specific antigens via a surface TCR. As such, understanding the canine T cell response to vaccines, cancer, immunotherapies, and infectious diseases is critically important for both dog and human health. Off-the-shelf commercial reagents, kits and services are readily available for human, non-human primate, and mouse in this context. However, these resources are limited for the canine. In this study, we present a cost-effective protocol for analysis of canine TCR beta chain genes. Workflow can be accomplished in 1-2 days starting with total RNA and resulting in libraries ready for sequencing on Illumina platforms.

Indexed as

Receptors, Antigen, T-Cell, alpha-betaT-LymphocytesAnimalsDogsHigh-Throughput Nucleotide SequencingMiceReceptors, Antigen, T-Cell, alpha-betaComparative oncologyDogIllumina sequencingImmune profilingSpontaneous canine malignant melanomaT cell receptor beta chain

Identifiers

PMID38183837
PMCPMC10872364
OpenAlexW4389612933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.